Oxford Biomedica expands COVID-19 deal with AstraZeneca

4 July 2022

UK cell and gene therapy company Oxford Biomedica (LSE: OXB) on Friday announced that it has signed a new three-year master services and development agreement (MSDA) with AstraZeneca (LSE: AZN), which would facilitate potential future manufacturing opportunities for the AstraZeneca COVID-19 vaccine.

This represents an expansion of the original MSDA announced between the two companies in September 2020, and news of the expansion edged Oxford Biomedica’s shares up 2.6% to 466.00 pence. Before AstraZeneca partnered with Oxford University to develop its Covid vaccine, the pharmaceutical pharma did not have a significant vaccine business.

The manufacture of COVID-19 vaccines at Oxford Biomedica’s Oxbox facility is expected to complete in the last quarter of 2022, as part of the original commitment. In accordance with the terms of the original agreement and inclusive of revenues for batches already manufactured in the first half of 2022, Oxford Biomedica expects to recognize aggregate revenues of approximately £30 million ($36 million) from AstraZeneca in the current financial year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK